COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept - Université de Montpellier Accéder directement au contenu
Autre Publication Scientifique Anaesthesia Critical Care & Pain Medicine Année : 2020

COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept

Résumé

At the time of this writing, > 3 million cases of the SARS-CoV-2 virus-induced human disease, the Coronavirus disease 2019 (COVID-19), have been reported worldwide with > 210,000 deaths. Although the lungs are ‘‘ground zero’’ [1], the virus’s reach can extend to any organs including the heart and blood vessels, kidneys, gut and brain. Evidence of abnormal coagulation markers in COVID-19 appeared in early reports from China [2]. It includes elevated fibrinogen and D-dimers, minimal changes in PT, PTT and platelet count in early stages of infection, no antithrombin deficiency, coagulopathy being related to severity of illness, overt Disseminated Intravascular Coagulation (DIC; ISTH criteria) being an end-stage evolution in the most severe cases, mainly in non- survivors. Further studies evidenced elevated D-dimers on admission (> 1000 ng/mL) associated with increased mortality [3]. Then accumulating reports described a high incidence of venous thromboembolic events VTE, also of arterial events, in ICU patients. The COVID-19 associated coagulopathy (CAC) quickly became an issue of clinical management, hoping to limit deleterious clinical consequences and improve the prognosis.

Dates et versions

hal-03579017 , version 1 (17-02-2022)

Identifiants

Citer

Jean-Christophe Gris, Antonia Perez-Martin, Isabelle Quéré, Albert Sotto. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. 2020, pp.381-382. ⟨10.1016/j.accpm.2020.04.013⟩. ⟨hal-03579017⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More